Targeted radiotherapy for pancreatic cancer
Official title: Optimized targeted radiotherapy of pancreatic cancer
Funded at Oncotab, INC · NIH-11069517 · Data updated 2026-11-12
This study is looking at a new treatment for advanced pancreatic cancer by using a special antibody called TAB004 that helps deliver radiation directly to the cancer cells, making the treatment more effective for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncotab, INC NIH-funded |
| Lab location | 1 site (Charlotte, United States) |
| Project start | June 1, 2025 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $400,000 |
| NIH project number | 1R41CA284997-01A1 |
| Project ID | NIH-11069517 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with advanced or metastatic disease.
✕Less likely to help
Patients with early-stage pancreatic cancer who can undergo surgical removal of their tumors may not benefit from this targeted therapy approach.
What this research studies
This research focuses on improving treatment options for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with a low survival rate. The approach involves developing a specific antibody, TAB004, that targets a protein found on the surface of cancer cells, allowing for more effective delivery of radiotherapy. By overcoming the challenges posed by the tumor's stroma, which hinders drug delivery, this research aims to enhance the effectiveness of treatment for patients with advanced pancreatic cancer. The study will explore the use of a fully humanized version of the antibody for targeted radiotherapy and imaging.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results with similar targeted therapies in other cancer types, indicating potential for success in this novel approach for pancreatic cancer.
Where this research is happening
-
Oncotab, INC
Charlotte, United States Active
Researchers
- Principal investigator: Mukherjee, Pinku — Oncotab, INC
- Study coordinator: Mukherjee, Pinku
Related research
Other NIH-funded projects on the same topics.
-
In situ cancer cell mineralization to boost radiotherapy for pancreatic cancer
Aims to help pancreatic cancer patients by using tiny gold minerals made inside cancer cells to improve radiotherapy effectiveness while sparing healthy tissue.
-
Real-time MRI-guided adaptive radiation for inoperable pancreatic cancer
This approach uses real-time MRI to guide high-dose, focused radiation for people with pancreatic tumors that cannot be removed by surgery.
-
Improving Radiation Treatment for Pancreatic Cancer with Targeted Nanoparticles
This work explores a new way to deliver tiny particles directly to pancreatic cancer cells, aiming to make radiation therapy more effective for patients.
-
Using real-time MRI to improve radiation therapy for pancreatic cancer
This study is looking at a new way to make radiation therapy better for people with pancreatic cancer that can't be surgically removed, using special MRI technology to track tumor movement and deliver radiation more accurately, which could help improve treatment results while protecting healthy tissue.
-
Using gold nanoparticles to improve radiation treatment for pancreatic cancer
This study is testing a new way to make radiation therapy work better for people with pancreatic cancer by using tiny gold particles that can be delivered right to the cancer cells, helping to target the tumor more effectively while protecting healthy tissue.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.